Goal-Oriented Therapy Evaluated By Cardiopulmonary Exercise Testing For Pulmonary Arterial Hypertensio
- Conditions
- Pulmonary arterial hypertension
- Registration Number
- JPRN-UMIN000006174
- Lead Sponsor
- Department of Cardiology, Nagoya University Graduate School of Medicine
- Brief Summary
The primary endpoint was cardiovascular death. In the goal-oriented therapy group, plasma brain natriuretic peptide, mean pulmonary arterial pressure, pulmonary vascular resistance, and 6-min walk test were significantly improved at 12 months compared with baseline. Survival in the goal-oriented therapy group at 1, 2, and 3 years (97.6%, 95.2%, and 86.0%, respectively) tended to be higher than that in the conventional empiric therapy group (P=0.082).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 129
Not provided
1) Pulmonary hypertension due to left heart disease, Pulmonary hypertension due to lung diseases and/or hypoxia, Chronic thromboembolic pulmonary hypertension 2) Pregnant 3) Moderate or severe hepatic failure patients 4) More than 2.0 mg/dl Serum creatinine levels 5) Severe interstitial lung disease 6) Coronary artery disease 7) The patients can not walk by themself. 8) The patients who have taken medications for PAH treatment drugs including the pill PGI2, endothelin receptor antagonists, phosphoesterase inhibitors-5, and intravenous epoprostenol 9) Inappropriate patients due to other reasons
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Admission due to right heart failure, syncope, arrythmia, and hemoptysis. induction of intravenous epopresterol. Cardiac death.
- Secondary Outcome Measures
Name Time Method Exercise tolerance (cardiopulmonary exercise testing, 6-minutes walk distance, WHO functional class, hemodynamics, BNP, QOL score by HADS, SF-8, and PMADL 8. induction of oxygen therapy